Target intelligence / Profile preview

Mitogen-activated protein kinase 3 (MAPK3) (MAPK3)

Target
MAPK3
Molecular classification
Enzyme, Kinase, Serine/threonine-protein kinase
01

Overview

Mitogen-activated protein kinase 3 (MAPK3), also known as extracellular signal-regulated kinase 1 (ERK1), is a serine/threonine kinase that serves as a critical node in the highly conserved Ras-Raf-MEK-ERK signal transduction cascade. Activated by dual phosphorylation on Thr202 and Tyr204 by upstream MEK1/2 kinases, MAPK3 translocates from the cytoplasm to the nucleus. Once in the nucleus, it phosphorylates numerous transcription factors and cytosolic substrates to regulate essential cellular processes, including cell proliferation, survival, differentiation, and apoptosis. Aberrant hyperactivation of the MAPK/ERK pathway, often driven by upstream oncogenic mutations in RAS or BRAF, is a hallmark of various malignancies, including melanoma, colorectal cancer, non-small cell lung cancer, and pancreatic cancer. Consequently, MAPK3/ERK1 represents a major therapeutic target, particularly for overcoming acquired resistance to upstream RAF and MEK inhibitors. Small-molecule inhibitors targeting MAPK3/ERK1, such as ulixertinib and temuterkib, are currently under clinical investigation to block this pathway, suppress tumor growth, and manage inflammatory conditions.

Other names
Extracellular signal-regulated kinase 1ERK-1ERK1MAP kinase 3MAPK 3p44-ERK1p44-MAPKERT2Insulin-stimulated MAP2 kinaseMicrotubule-associated protein 2 kinase
02

Mechanism of action

Reversible or irreversible ATP-competitive inhibition of ERK1/2 kinase activity, blocking downstream phosphorylation of substrates such as RSK and transcription factors.

03

Biological functions

Signal transductionCell proliferationCell cycleApoptosisCell differentiationCell survivalMeiosisMitosis
04

Disease associations

CancerInflammationNeurodegenerative diseaseCardiovascular disease
05

Safety considerations

Central serous retinopathy (CSR) / ocular toxicitiesDermatologic toxicities (e.g., acneiform rash)Gastrointestinal toxicities (e.g., diarrhea, nausea, vomiting)FatigueHepatotoxicityCardiovascular toxicities (e.g., QTc prolongation)
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

Phospho-ERK1/2 (p-ERK1/2) levelsPhospho-RSK (p-RSK) levelsBRAF mutation statusKRAS mutation statusNRAS mutation statusERK1/2 pathway activation level (PAL)

Beyond the preview

Go deeper on Mitogen-activated protein kinase 3 (MAPK3) (MAPK3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitogen-activated protein kinase 3 (MAPK3) (MAPK3).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call